EP300/CREBBP inhibitor exhibited promising therapeutic potential by disrupting MLL-r-BET transcript complex binding to H3K27Ac on key gene loci distinct from global histone acetylation, and disrupting critical signaling pathways in MLL-r AML. Here, KMT2A is linked to acute myeloid leukemia.